Cervical cancer is a major cause of morbidity and mortality worldwide, particularly in countries which do not have organized screening programs. Cervical cancer is mostly induced by human papilloma virus (HPV) and is the second most common cancer and the third leading cause of death in women worldwide after breast and lung cancer.
Human papillomaviruses are classified in their own family, the Papillomaviridae. The Papillomaviridae family comprises a huge number of subfamilies with more than 200 serotypes. In different regions of the world, different serotypes are dominant. Current HPV vaccines are mainly effective against the most common serotypes in the western world, namely HPV 16 and 18.
Redbiotec’s chimeric HPV VLPs contain a mixture of L1 proteins from different serotypes incorporated into a single VLP. The flexible design of the particles allows access to further HPV serotypes for broader protection against cervical cancer. In addition, Redbiotec’s technology allows for fast and cost-efficient production of the vaccine.